AAPL   315.01 (-0.54%)
MSFT   179.89 (-0.93%)
FB   227.04 (-2.22%)
GOOGL   1,412.72 (-0.61%)
AMZN   2,389.96 (-1.32%)
CGC   19.46 (-2.75%)
BABA   199.06 (-1.32%)
MU   44.87 (-2.03%)
GE   7.31 (+7.50%)
TSLA   808.36 (-1.28%)
AMD   50.93 (-4.25%)
T   31.83 (+3.24%)
ACB   15.11 (-3.20%)
F   5.99 (+2.57%)
DIS   121.56 (+0.50%)
BAC   25.66 (+5.68%)
BA   146.15 (+0.98%)
AAPL   315.01 (-0.54%)
MSFT   179.89 (-0.93%)
FB   227.04 (-2.22%)
GOOGL   1,412.72 (-0.61%)
AMZN   2,389.96 (-1.32%)
CGC   19.46 (-2.75%)
BABA   199.06 (-1.32%)
MU   44.87 (-2.03%)
GE   7.31 (+7.50%)
TSLA   808.36 (-1.28%)
AMD   50.93 (-4.25%)
T   31.83 (+3.24%)
ACB   15.11 (-3.20%)
F   5.99 (+2.57%)
DIS   121.56 (+0.50%)
BAC   25.66 (+5.68%)
BA   146.15 (+0.98%)
AAPL   315.01 (-0.54%)
MSFT   179.89 (-0.93%)
FB   227.04 (-2.22%)
GOOGL   1,412.72 (-0.61%)
AMZN   2,389.96 (-1.32%)
CGC   19.46 (-2.75%)
BABA   199.06 (-1.32%)
MU   44.87 (-2.03%)
GE   7.31 (+7.50%)
TSLA   808.36 (-1.28%)
AMD   50.93 (-4.25%)
T   31.83 (+3.24%)
ACB   15.11 (-3.20%)
F   5.99 (+2.57%)
DIS   121.56 (+0.50%)
BAC   25.66 (+5.68%)
BA   146.15 (+0.98%)
AAPL   315.01 (-0.54%)
MSFT   179.89 (-0.93%)
FB   227.04 (-2.22%)
GOOGL   1,412.72 (-0.61%)
AMZN   2,389.96 (-1.32%)
CGC   19.46 (-2.75%)
BABA   199.06 (-1.32%)
MU   44.87 (-2.03%)
GE   7.31 (+7.50%)
TSLA   808.36 (-1.28%)
AMD   50.93 (-4.25%)
T   31.83 (+3.24%)
ACB   15.11 (-3.20%)
F   5.99 (+2.57%)
DIS   121.56 (+0.50%)
BAC   25.66 (+5.68%)
BA   146.15 (+0.98%)
Log in

NASDAQ:ENTAEnanta Pharmaceuticals Stock Price, Forecast & News

$51.62
-3.31 (-6.03 %)
(As of 05/27/2020 12:42 PM ET)
Add
Compare
Today's Range
$51.50
Now: $51.62
$55.44
50-Day Range
$47.48
MA: $52.83
$57.58
52-Week Range
$38.40
Now: $51.62
$101.27
Volume72,835 shs
Average Volume144,336 shs
Market Capitalization$1.03 billion
P/E Ratio46.09
Dividend YieldN/A
Beta0.5
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Read More
Enanta Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$205.20 million
Cash Flow$2.15 per share
Book Value$24.29 per share

Profitability

Net Income$46.38 million

Miscellaneous

Employees113
Market Cap$1.03 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

How has Enanta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENTA shares have decreased by 2.5% and is now trading at $51.62. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Enanta Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Enanta Pharmaceuticals.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.73) by $0.43. The biotechnology company had revenue of $27.60 million for the quarter, compared to the consensus estimate of $29.16 million. Enanta Pharmaceuticals had a return on equity of 5.04% and a net margin of 13.46%. The company's revenue was down 30.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.20 EPS. View Enanta Pharmaceuticals' earnings history.

What price target have analysts set for ENTA?

6 equities research analysts have issued 1 year price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $49.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $71.60 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

News headlines about ENTA stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutEnanta Pharmaceuticals.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,600,000 shares, a decline of 8.6% from the April 30th total of 1,750,000 shares. Based on an average daily volume of 225,700 shares, the days-to-cover ratio is currently 7.1 days. Approximately 9.1% of the company's shares are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), Gilead Sciences (GILD), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH) and Netflix (NFLX).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.21%), State Street Corp (4.56%), Krensavage Asset Management LLC (3.50%), First Manhattan Co. (2.07%), Acadian Asset Management LLC (1.73%) and Deutsche Bank AG (1.32%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View institutional ownership trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Invesco Ltd., First Manhattan Co., AJO LP, AQR Capital Management LLC, Two Sigma Investments LP, and Nuveen Asset Management LLC. View insider buying and selling activity for Enanta Pharmaceuticals.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Deutsche Bank AG, Grantham Mayo Van Otterloo & Co. LLC, State Street Corp, International Biotechnology Trust PLC, Aviva PLC, Two Sigma Advisers LP, and BNP Paribas Arbitrage SA. View insider buying and selling activity for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $51.62.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.03 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.